On November 17, 2026, JD Health International Inc. (HKEX: 06618 for HKD counter and HKEX: 86618 for RMB counter) released its financial results for the third quarter of 2026.
During the reporting period, JD Health recorded revenue of RMB 20.02 billion and Non-IFRS operating profit of RMB 1.57 billion.
In the third quarter, the company continued to strengthen its core pharmaceutical and healthcare supply chain capabilities, deepened the application of AI across all medical service scenarios, and accelerated the buildout of its offline closed-loop model spanning medical consultation, health screening, diagnosis, and pharmacy.
Meanwhile, leveraging the 9th China International Import Expo (CIIE), JD Health further expanded its global partner network, achieving steady growth alongside a pronounced high-quality development trajectory.
Over 50 New Drugs Launched in a Single Quarter as CIIE Expands Global Partnerships
In the third quarter, JD Health maintained its industry-leading position in new drug launches and pharmaceutical company partnerships.
As of September 30, 2026, more than 110 pharmaceutical companies had chosen JD Health as their launch partner for new products.
During the third quarter, over 50 new drugs made their debut on JD Health, including Yangtze River Pharmaceutical Group's innovative drug Bailemian, GeneScience Pharmaceuticals' domestic gout innovation drug Jinbeixin, and Hengrui Pharmaceuticals' new drug Hengyi.
At the same time, the company deepened collaboration with partners such as LEO Pharma, Everest Medicines, and Likang Life Sciences to jointly explore innovative service models centered on AI-empowered specialty patient services and full-course chronic disease management.
While reinforcing pharmaceutical supply, JD Health also made substantial progress in medical devices, nutritional health products, and pet categories and services.
In high-end medical devices, the company partnered with the Boao Lecheng Pilot Zone Administration in the third quarter to jointly launch the JD Health Boao Lecheng High-End Device Zone, covering premium categories such as diagnostic testing, health monitoring, and rehabilitation care, helping global medical device innovations reach domestic users more quickly.
In health consumption, the company fully upgraded its "Medical Gold Selection" product curation mechanism, partnering with nearly 20 leading brands including Johnson & Johnson, Durex, and Comfy to bring high-quality medical personal care products to the mass market more rapidly.
Additionally, the company continued to refine its closed-loop pet health service model covering medical care, testing, medication, and insurance, partnering with brands such as Royal Canin to advance the gold selection of pet prescription food, and optimizing cold-chain fulfillment and service guarantees for pet vaccines.
This supply chain ecosystem advantage was showcased prominently at the 9th CIIE in November.
During the expo, JD Health signed agreements with more than 20 global pharmaceutical and health brands including Pfizer, Merck, Novo Nordisk, and Takeda, with cooperation expanding from new product launches to patient management, AI innovation, and full-course health management.
As of the third quarter, JD Health had launched over 100 new drugs online, exceeding the total for all of 2025, further consolidating its industry position as the top platform for nationwide new drug launches.
Meanwhile, through brand partnerships and new drug and health product launches, JD Health continued to enrich its global supply, strengthening the user perception that "buy global quality medicine on JD."
In omnichannel fulfillment, JD Health's instant medication delivery service steadily expanded its coverage and partner pharmacy network.
Through collaboration with partner pharmacies, 24-hour online pharmacist support, and one-on-one express delivery, nighttime medication services had expanded to over 300 cities nationwide.
The company also upgraded existing cold-chain delivery services in multiple cities, achieving temperature-controlled delivery and real-time monitoring for hundreds of drug types, continuously improving omnichannel pharmaceutical fulfillment capabilities.
AI Doctor "Dawei" Interaction Volume Up Over 5x as Medwork Empowers Clinical Practice
In the third quarter, JD Health's AI medical service experience continued to improve.
The AI doctor "Dawei" maintained rapid user growth, with average daily AI health service interactions increasing more than fivefold year-on-year.
In specialty health management, the company partnered with expert teams including Professor Wang Xiaoping from Xiangya Second Hospital of Central South University, Professor Li Zhanjiang from Beijing Anding Hospital, and Professor Yang Dingquan from China-Japan Friendship Hospital to jointly launch celebrity doctor AI agents in dermatology, psychology, respiratory, and chronic metabolic disease fields, providing personalized health consultations and long-term continuous follow-up.
Furthermore, JD Health's doctor AI workstation Medwork achieved breakthrough progress.
Powered by the "Jingyi Qianxun" large model, Medwork deeply embeds AI into clinical doctor workflows, covering diagnostic and treatment decision support, multidisciplinary consultation, clinical evidence verification, and full-process research support such as 3D image reading and draft paper generation.
It also launched the "Zhiyi Academy" module to support doctors' academic development.
Through a strategic partnership with Yunque Medical, the company further expanded its reach to grassroots and rural doctors.
In specialty model deployment, the company has initiated pilot programs with top teams including Peking University Cancer Hospital, Shandong First Medical University Affiliated Cancer Hospital, and the First Affiliated Hospital of Guangzhou Medical University, covering gastrointestinal tumors, lung cancer, and respiratory diseases.
JD Health Opens New Physical Examination Centers, Accelerating Offline Closed-Loop Model
In integrating online and offline full-scenario services, JD Health continued to expand the service radius of its offline medical examination, diagnosis, and pharmacy model.
Currently, users can book over 400 testing and examination items online, of which 160 are at-home testing services.
CT and MRI imaging examinations have been established in 15 cities nationwide.
JD Health's comprehensive outpatient clinics at Beijing Yaao and Tongzhou locations opened successively, offering physical examinations, dental care, and medical aesthetics services simultaneously, along with closed-loop management features such as free re-examination within 180 days for over 200 abnormal indicators and one-on-one private doctor accompaniment, making high-quality offline medical services more accessible.
At the same time, leveraging its continuously improving medical and health service capabilities, the company recently officially launched its "Medical Tourism to China" business, connecting global patients with China's high-quality medical resources.
In the third quarter, JD Nurse at Home officially launched its "Filial Care" service.
Licensed nurses visit regularly each week to measure blood pressure, blood sugar, and blood oxygen for elderly individuals, establish family health records, continuously track changes in physical indicators, diet, exercise, and daily conditions, promptly alert to potential health risks, and provide professional care recommendations.
Centered on scenarios including home health management for the elderly, chronic disease care, rehabilitation nursing, and family caregiving support, JD Health continues to explore health service models better suited to Chinese families through its nurse-at-home service, making professional medical and health services more conveniently accessible within the home.
In the third quarter of 2026, with "AI plus supply chain" as its core driving force, JD Health not only maintained strong momentum in online new drug launches and AI medical services but also continued to solidify its full-scenario health service foundation through the deepening of its medical examination, diagnosis, and pharmacy model and the expansion of its global partnerships at CIIE.
In the future, JD Health will continue to explore innovative service models to provide users with more professional, convenient, and accessible comprehensive health solutions.
Comments